Navigation Links
Bowel Cancer and Lifestyle Choices

Bowel cancer is a deadly disease. Yet recent studies have shown that the chance of developing it being liked to lifestyle choices such as diet and exercise//, the chances of surviving it, also depend on the same factors.

The World Cancer Research Fund is putting around 50,000 pounds behind a study to be carried out by Dundee University, Scotland.

The three-month study will involve cancer survivors aged above fifty and with a BMI (Body Mass Index) above 25 who will be put on a monitored diet and exercise.

Levels of vitamin C as well as measures of weight will be carried out during this period. A note of the challenges faced by the participants will also be taken.

The researchers hope for changes such as weight loss of about five percent, 150 minutes of physical activity per week and healthier diet patterns.

The study is named ‘LiveWell’ and hopes to establish a correlation between BMI, exercise and rate of recurrence and survival of the cancer.

Survival rates of this cancer have improved considerably over the last years. A survival rate of 50 percent of patients, five years after diagnosis of the disease now is quite common.

Says Professor Annie Anderson, one of the leaders of the study, "Research has shown a link between the primary development of bowel cancer and diet and lifestyle factors. Being overweight and inactive, for example, can increase its risk. There is some evidence out now that survival might also be influenced by levels of activity and diet."


AN
'"/>




Page: 1

Related medicine news :

1. Bowel diseases linked to bug in milk
2. Hope For Patients With Inflammatory Bowel Disease
3. Cannabinoids - Antidepressant And Inflammatory Bowel Disease Treatment
4. Eating Red and Processed Meat may cause Bowel cancer
5. Just Had Bowel Surgery? Chew Gum For A Speedy Recovery
6. Delay In Life-Saving Bowel Cancer Screening Programme In UK
7. National Bowel Cancer Screening Programme Lauded
8. Bowel Cancer Drug Campaigner Dies After Surgery
9. New compounds Help Sustain relief For Patients With Symptoms of Bowel Disorders
10. Parasitic Worms Could Be Used To Treat Bowel Disease
11. Inflammatory Bowel Diseases Cured By Parasitic Worms
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Bowel Cancer and Lifestyle Choices

(Date:12/4/2008)...h anniversary of drive to eliminate lymphatic fila...zole tablet and grant to The Carter Center , ,...rstCall/ -- In a meeting today with former U.S. Pr...rter, as well as global health thought leaders fro...SK ) announced that it has made a $250,000 donatio...
(Date:12/4/2008)...ewswire/ -- Two researchers who translate math int...n stopping breast cancer in its,tracks are this y...tific,Distinction in basic research and clinical ...onio, Susan G. Komen for the Cure(R) announced tod...in/prnh/20070122/NYM084LOGO ) , Award recip...
(Date:12/4/2008)...c. 4 MiddleBrook,Pharma... that it has opened its,administrative and sales ...wn,facility will continue to house certain person...ch and development group. The newly leased 14,971...se up to 60 employees as MiddleBrook,grows. , ...
(Date:12/4/2008)...., Dec. 4 Universal Heal...oday that they have expanded their,Board of Trust... Vice,President of Universal Health Services, Inc...ears of experience in healthcare leadership roles.... Co-head of the Acute Care Division,since 2007 an...
Breaking Medicine News(10 mins):Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 2Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 3Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 4Health News:Susan G. Komen for the Cure(R) Announces Recipients of 2008 Komen Brinker Award for Scientific Distinction 2Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 2Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 3Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 4
...men at high risk of getting breast cancer in UK ar... Imaging) scans between the ages of 20-49//. Studi...,000 women yearly in the UK can be detected by the...e breast cancer cases are hereditary. Women with a...
...New Zealand scientist warned Wednesday of sophisti...ke medicines that kill thousands of people every y...it pills not only lacked the proper ingredients to...ontained carcinogens, solvents and even remains of...
...pe has been found to be a common crime with studie...n has committed rape at least once//. These shock...earch unit of the country's Medical Research Counc...of ages of 15 to 26 years revealed about 8 per cen...
...okers will be denied life-changing operations unle...oday. Many cash-strapped hospitals say that they w...ts// until they are going to give up on smoking. T...so be denied treatment. Smokers are at a big ris...
Other Medicine News:Health News:New Zealand Scientist Warns On Fake Drugs 2Health News:Smokers Warned to Give up else Face Denial of Operations 2Health News:Smokers Warned to Give up else Face Denial of Operations 3
(Date:12/3/2008)...wire/ -- Roche today announced that the U.S. Food ... guidance on the requirements for the Biologics Li...b), the first interleukin-6 (IL-6) receptor-inhibi... of adult patients with moderately to severely act...sult of the FDA,s evolving Risk Evaluation and Mit...
(Date:12/3/2008)...PRNewswire/ -- The Leukemia & Lymphoma Society...ing of a new clinical trial of ISF35, a cancer vac... (UCSD). , , LLS is collaborating on this...ment and approval of a novel approach aimed at tre...17p deleted chronic lymphocytic leukemia (CLL). ,...
(Date:12/3/2008)...Newswire-FirstCall/ -- Isis Pharmaceuticals,Inc....Pharmaceuticals, Inc.,provided positive survival ...f,OGX-011 in combination with docetaxel and predn...nd prednisone alone ("the control arm") for first-...rostate cancer. The current 10.6,month median ov...
(Date:12/2/2008)...USNewswire/ -- Researchers using functional,MRI (...ea of the brain,responsible for suppressing memor...ess-related psychiatric disorders. Results of the ...ng of the Radiological Society of North America,(...n and other stress-related disorders,traumatic m...
Breaking Medicine Technology:Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab) 2Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab) 3Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab) 4Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab) 5The Leukemia & Lymphoma Society and Memgen Announce New Chronic Lymphocytic Leukemia Clinical Trial 2The Leukemia & Lymphoma Society and Memgen Announce New Chronic Lymphocytic Leukemia Clinical Trial 3Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 2Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 3Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 4Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Higher Risk of Death for Babies Born Just a Few Weeks Early Study Finds 6149 1Higher Risk of Death for Babies Born Just a Few Weeks Early Study Finds 6149 2Cardiome To Release Third Quarter Results 6147 1Cardiome To Release Third Quarter Results 6147 2Cardiome To Release Third Quarter Results 6147 3Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 840 1Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 840 2Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 840 3Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 840 4Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 840 5Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 840 6Caraco Pharmaceutical Laboratories Ltd Announces Tentative FDA Approval for Generic Lamictal 28R 29 6145 1Caraco Pharmaceutical Laboratories Ltd Announces Tentative FDA Approval for Generic Lamictal 28R 29 6145 2
... 66.1 weeks for the,satraplatin arm compared with ...0.64 (95% CI: 0.51-0.79, p<0.001), representing,a ...sion, MARTINSRIED/MUNICH, Germany, May 21, 2007 /P...ER, Colo. -- GPC Biotech AG and,Pharmion Corporati...data from the double-blind, randomized satraplatin...
...ut of ten patients taking,once-daily Lialda remain...N, D.C., May 22, 2007 /PRNewswire-FirstCall/ -- A,...ion study (303),presented at the British Society o...and in March 2007 showed Shire plc,s,Lialda(mesala...ients. Today, secondary endpoints of study 303 wer...
Other Medicine Technology:Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 2Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 3Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 4Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 5Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 6Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 2Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 3Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 4Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 5Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 6Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 7Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 8
Merocel Ophthalmic Products provide the surgeon with fiber free products for fluid,control and safe cleaning of fine microsurgical instruments. The exclusive Merocel,material is highly absorbent,
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box.
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box.
Accu-Temp Cauteries provide a broad selection of tip styles for cauterization in a wide variety of ophthalmic procedures. Each single use cautery is packaged sterile, complete with a safety cap to lo
Medicine Products: